ArticleJournal of the International AIDS Society2025
The persistent chasm between PrEP awareness and uptake: characterizing the biomedical HIV prevention continuum in a nationwide cohort of transgender women in the United States and Puerto Rico.
Article in Journal of the International AIDS Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
introductionTransgender (trans) women are disproportionately impacted by HIV, yet data on the biomedical HIV PrEP continuum (HIVPC) among trans women are limited. We characterized the HIVPC among a large, nationwide cohort of trans women in the United States and Puerto Rico by pre-exposure prophylaxis (PrEP) modality (daily oral and long-acting injectable, LAI) and identified correlates of uptake and non-adherence.
methodsFrom April 2023 to December 2024, we enrolled English and Spanish-speaking adult trans women (age 18 years or older) not living with HIV (laboratory-confirmed via fourth-generation HIV-1/2 antigen/antibody testing) and residing in the United States and Puerto Rico into the cohort. PrEP data were collected via self-administered surveys. We characterized the HIVPC using descriptive statistics and assessed for differences in proportions for each step of the HIVPC by modality. Modified Poisson regression models estimated adjusted prevalence ratios (aPR) and 95% confidence intervals (95% CI) for correlates of HIVPC step (e.g. awareness to uptake).
resultsWe enrolled 2504 participants, 1636 (65%) of whom may have benefitted from PrEP based on self-reported sexual history and/or needle sharing in the prior 6 months at baseline. Forty-two percent were 18-29 years old, 18% identified as Hispanic and/or Latina/x/e and 13% identified as Black (inclusive of multiracial participants). Among participants who may have benefitted from PrEP, 92% (n = 1495) had ever heard of PrEP, 36% (n = 591) had ever used PrEP, 27% (n = 441) had recently used PrEP (past 6 months) and 20% (n = 330) were adherent. The largest proportional difference in HIVPC step was from awareness to uptake (60% of PrEP-aware participants had never used PrEP). This difference was significantly greater for LAI PrEP (96% of LAI PrEP-aware participants had never used LAI). Correlates of PrEP uptake included high perceived HIV acquisition risk (aPR = 2.08, 95% CI = 1.59-2.72; ref = no perceived risk), current use of exogenous oestrogen and/or anti-androgens (aPR = 1.47 95% CI = 1.21-1.79), and receipt of health services at an LGBTQ+ clinic (aPR = 1.34, 95% CI = 1.16-1.55). Correlates of non-adherence among PrEP users included being a non-U.S. citizen (aPR: 2.41, 95% CI = 1.44-4.05) and recent food insecurity (aPR: 1.47, 95% CI = 1.04-2.06).
conclusionsInterventions to improve HIVPC outcomes-especially PrEP uptake-are needed to optimize HIV PrEP among trans women. PrEP interventions may need to include individually tailored, integrated programming to address risk perception, nutrition, gender-affirming care and comprehensive health, social, and legal needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.